IR Overview

Cyclo Therapeutics, Inc. (OTCQB: CTDH)

Cyclo Therapeutics, Inc. is a biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need. The company’s Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe, is in three ongoing formal clinical trials for Niemann-Pick Disease Type C, a rare and fatal genetic disease, (Clinical Trials.gov NCT02939547, NCT02912793 and NCT03893071) and in an Expanded Access program for late-onset Alzheimer’s Disease (NCT03624842). Additional indications for the active ingredient in Trappsol® Cyclo™ are in development. For additional information, visit the company’s website: www.cyclotherapeutics.com

The CTD division provides the world’s widest range of cyclodextrin-based fine chemicals available from a single source in  both research and commercial quantities to life science laboratories and commercial manufacturers world-wide. For additional information, visit the division’s website: www.cyclodex.com

Recent News


Company Information

CTD Holdings, Inc.
P.O. Box 1180
Alachua, FL 32616

Issue Type: Common Stock
Sector: Healthcare
Industry: Drugs

Management Team

N. Scott Fine
Chairman & CEO

Dr. Jeffrey L. Tate
Director, COO & CQO

Dr. Sharon H. Hrynkow
CSO & SVP of Medical Affairs


Investor Relations

Sitrick and Company
Wendy Tanaka
11999 San Vicente Blvd
Los Angeles, CA 90049
415-369-8447

Transfer Agent

VStock Transfer, LLC
18 Lafayette Place
Woodmere, NY 11598
212-828-8436

Auditors

WithumSmith+Brown, PC
200 S. Orange Ave, Suite 1200
Orlando, FL 32801
407-849-1569